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ABSTRACT 
TRUNCATED MORTALIN IN ANIMAL CANCER 
By 
Katrina K. Olson 
University of New Hampshire, May, 2010 
Hematopoetic neoplasia or clam hemocyte cancer (a leukemia-like 
disease) has been studied in a number of bivalve molluscs for the last 20 years. 
Recent molecular studies of the hemocytes of the soft shell clam, Mya arenaria, 
have demonstrated an interaction between p53 and mortalin, the mitochondrial 
Hsp70. The former protein is intimately involved in the initiation of cell-cycle 
arrest, apoptosis, DNA repair, and cell differentiation. In cancerous clams, wild-
type p53 is sequestered in hemocyte cytoplasm by mortalin and cannot be 
translocated to the nucleus. This is critical because although p53 is functions 
properly, it is unable to enter the nucleus and initiate cell-cycle arrest. This allows 
the immortality of cancerous clam hemocytes (CCH). In CCH, wild-type p53 can 
be induced to enter the nucleus and trigger apoptosis genotoxically following 
treatment with the topoisomerase II inhibitor, etoposide, or non-genotoxically with 
the dye, MKT-077. Full-length and truncated (missing exon 3) clam variants of 
human mortalin have recently been cloned. 
Here I have generated and purified an antibody to the truncated variant of 
clam mortalin and have attempted to determine its location within cancerous 
clam hemocyte cytoplasm. 
I point out problems with the transfection of the truncated mortalin 
antibody into clam hemocyte cytoplasm and in localizing antibodies in cancerous 
clam hemocytes embedded in water-soluble resins. The results of this study 




On the North Eastern coast of the United States, the soft shell clam, Mya 
arenaria, develops a fatal blood cancer in >1% of virtually all populations 
investigated1. This bivalve cancer was first reported in 1977 in clams from 
Maine1. The disease has been called a systemic, disseminated neoplasia by the 
now defunct Registry of Tumors in Lower Animals (formerly maintained by the 
National Cancer Institute), although the most common descriptors in the literature 
are hemopoetic, hematopoetic, or hemic neoplasia2. I will use the phrase 
cancerous clam hemocytes (CCH) to describe these malignant cells. 
Amitotic normal clam hemocytes (NCH) phagocytize bacteria and other 
foreign particles from the hemolymph1. CCH undergo continuous mitosis and 
lose the ability to phagocytize1. CCH are immortalized cells, constantly replicating 
to accumulate in the blood sinuses within the gill, gonad, and digestive gland. 
Their increased numbers distort the size and function of these tissues1, 
increasing to a point where severe clam hemocyte cancer is fatal for clams3. The 
etiology of the disease has not been determined, although both viral agents and 
environmental pollutants have been suggested as potentially involved4. 
Recently, the cellular mechanisms responsible for clam hemocyte cancer 
have been investigated for Mya arenaria 56,7. In NCH, wild-type p53 is localized 
in both the cytoplasm and nucleus, while mortalin is only found in the cytoplasm7. 
In CCH, wild-type p53 co-localizes with mortalin in the cytoplasm when the latter 
is over-expressed7. P53 binds to the p53-binding domain of mortalin. Mortalin 
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retains wild-type p53 in the cytoplasm and, consequently, the transcriptional 
functions of p53 in DNA repair and/or apoptosis are negated. In humans, some 
patients with glioblastoma and colorectal carcinomas also display sequestration 
of wild-type p53 in the cytoplasm, although the mechanism for sequestering p53 
is not understood8'9. It is uncertain how the non-transcriptional, mitochondrial 
functions of p53 are affected in CCH by p53 sequestration. 
Mortalin is the mitochondrial Hsp70 and is a member of the Hsp70 family 
of proteins. Mortalin is involved in many different cellular activities including 
mitochondrial protein import, intracellular trafficking (e.g. p53), and receptor 
internalization10,11. 
Both full-length and truncated variants of clam mortalin protein have been 
cloned and contain a p53 binding site that is 97% conserved with human 
mortalin7,12. While the full-length variant of mortalin is over-expressed in 
cancerous clam hemocytes by 1,200-fold, this newly-discovered truncated 
variant is over-expressed 620-fold5. The truncated version of mortalin is missing 
exon 3, consisting of 90 amino acids from the ATP/ADP binding site, which also 
encodes an ATPase. Figure 1 indicates the 90 amino acids (highlighted in red 
and representing exon 3) that are missing from truncated mortalin. When p53 is 
bound to mortalin, the ATPase is responsible for hydrolysis of ATP to ADP. ATP 
binding is required for the association of mortalin with p53, as the ADP-bound 
form has a very slow exchange rate. Once mortalin is bound to p53, the 
hydrolysis of ATP to ADP allows mortalin to change its conformation and lock in 
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p53, with a high binding affinity by closing the binding pocket, and stabilizing the 
interaction11. 
When Hsp70 proteins are bound to ATP, they cannot act as chaperones 
for proteins11. It is uncertain how lacking the ATP/ADP binding domain will affect 
the chaperone activities of mortalin. Is the over-expression of truncated mortalin 
able to indefinitely bind p53, resulting in the inactivation of p53 in clam hemocyte 
cancer or does the loss of the ATPase domain, even with the over-expression of 
truncated mortalin, cause truncated mortalin to be unable to interact with p53 5'11. 
In this study, I have focused on two main objectives: 
Objectivel: To generate and purify an antibody specific for the splice sites of 
exons 2 and 4 of truncated clam mortalin. 
Objective 2: To use the antibody developed in Objective 1 to localize the 
truncated mortalin protein within cancerous clam hemocytes. 
Figure 1. Amino acid sequence of full length clam mortalin compared with human 
mortalin. The red portion indicates exon 3, the 90 amino acids that are missing 
from truncated clam mortalin11. 
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CHAPTER 1 - GENERATING AN ANTIBODY FOR TRUNCATED MORTALIN 
I. Objective I: To generate and purify an antibody specific for the splice site 
of exons 2 and 4 of truncated clam mortalin. 
Hypothesis I: An antibody can be generated for the sequence upstream 
and downstream of exon 3 that will identify truncated clam mortalin. 
II. MATERIALS AND METHODS 
Peptide Design and Generation 
A peptide was designed to the last 7 amino acids in exon 2 (LLPSRLR) 
and the first 7 amino acids in exon 4 (METVPYK) of truncated clam mortalin 
protein, the 14 amino acids adjacent to the splice site for exon 3. The peptide 
consisted of seven amino acids upstream (exon 2), LLPSRLR, and seven amino 
acids downstream (exon 4), METVPYK, of the exon splice site (Figure 2). Based 
on this amino acid sequence, the peptide, NH2-LLPSRLRMETVPYK-COOH, was 
ordered from New England Peptide LLC (Gardner, MA). 
BSA Conjugation to the Peptide 
In a 1.5 mL microcentrifuge tube, 10mg of Bovine Serum Albumin (BSA) 
were dissolved in 500 uL 0.2M sodium phosphate buffer (NaH2P04) (monobasic, 
pH 7.5 with 1 M sodium hydroxide (NaOH)). In a second 1.5 mL microcentrifuge 
tube, a 30-fold molar excess of the truncated mortalin peptide relative to the BSA 
concentration was dissolved in 500 uL of distilled water. The peptide solution was 
neutralized by the addition of 1 M NaOH drop-wise until a pH of 7 was reached, 
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utilizing pH paper to determine the pH of the peptide soluton. Both the peptide 
solution and the BSA solution were combined in a 15 mL Falcon tube. 
While being vortexed, 1 mL 20 mM glutaraldehyde was added drop-wise 
to the peptide/BSA solution. The peptide/BSA solution was agitated at room 
temperature for 30 minutes. Conjugation of the peptide to BSA was terminated 
by first adding 250 ul_ of 1 M glycine to the solution, and then agitating the 
solution at room temperature for 30 minutes. 
The peptide/BSA solution was placed into a 1 cm diameter boiled dialysis 
tubing (Spectrum Laboratories, California), and the tubing was sealed shut with a 
floating clip. Un-conjugated peptide and BSA were removed by exhaustive 
dialysis in 1X phosphate buffered saline (PBS). Exhaustive dialysis, ultrafiltration 
of the un-conjugated peptide/BSA, was performed by floating the peptide/BSA 
filled tubing in 1 L of 1X PBS (8 g NaCI, 0.2 g KCI, 0.2 g KH2P04 monobasic, 2.17 g 
Na2HP04-7H20 dibasic), while stirring at 6°C for 24 hours. After 24 hours, the 
tubing was placed into a new solution of 1X PBS and stirred at 6°C for another 
72 hours. The dialysate was emptied into a 50 mL Falcon tube and brought to a 
final volume of 20 mL with 1X PBS. 
Antibody Generation 
20 mL of conjugated peptide-BSA were sent to Pacific Immunology Corp 
(Ramona, CA). This solution, containing the 14 residue peptide-BSA complex, 
was used to immunize two rabbits, labeled 2273 and 2274. A pre-immune bleed 
was removed prior to immunization. Bleeds were removed approximately every 
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two weeks following initial injection, yielding six bleeds on 10/1/07, 10/15/07, 
10/29/07, 11/12/07, 11/19/07, and 11/22/07. 
Establishing Relative Antibody Concentrations 
A 10 mg/mL solution of BSA was made in 10 ml_ 0.1 M sodium 
bicarbonate. Six umoles of the 14 residue peptide were dissolved in 1 mL 
distilled water. The peptide solution was neutralized with 1 M NaOH to a pH 7, 
diluted in an equal volume of 0.2 M sodium bicarbonate, and chilled on ice, while 
Affi-Gel 10 beads (Bio-Rad Laboratories, California) were equilibrated to room 
temperature. 
A sintered glass funnel (containing a glass mesh) and glass stir rod were 
washed sequentially in distilled water, 100% alcohol, and distilled water. The Affi-
Gel 10 was placed into the funnel and stirred with the glass rod. After vacuum 
removal of excess liquid, the Affi-Gel was re-suspended in a small volume of 0.1 
M sodium bicarbonate. Using a sterile glass rod, the Affi-Gel beads were mixed 
and placed in a 50 mL Falcon tube. The volume was adjusted to 50 mL with 0.1 
M sodium bicarbonate to make a 50% suspension of the Affi-Gel 10 beads. 
The slurry was mixed thoroughly, and 6 mL were poured into a 15 mL 
Falcon tube. The peptide solution was added to the slurry in the 15 mL Falcon 
tube, thoroughly agitated, and placed on Speci-Mix Rocker 
(Barnstead/Thermolyne, Dubuque, Iowa) overnight at 4°C to allow for adequate 
coupling. The BSA solution was treated the same way. The remaining Affi-Gel 
solution was combined with the BSA solution in a 50 mL Falcon tube, thoroughly 
agitated, and placed on the rocker overnight at 4°C. 
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Both Falcon tubes containing Affi-Gel beads were filled with 0.1 M sodium 
bicarbonate, and sequentially washed three additional times with the 0.1 M 
sodium bicarbonate. Between each wash, the Affi-Gel beads were centrifuged for 
1 minute at 10,000 RCF and placed under a vacuum to remove the 0.1 M sodium 
bicarbonate. Once the last wash was centrifuged and the sodium bicarbonate 
removed, a 1:1 ratio of 0.1 M ethanolamine HCI: Affi-Gel slurry was added to the 
Affi-Gel beads and placed on the rocker for 1 hour at room temperature to block 
any un-coupled sites on the affi-gel. 
Next, the beads were centrifuged for 1 minute at 10,000 RCF and the top 
aqueous layer was removed. The beads were washed in 0.1 M sodium 
bicarbonate containing 0.5 M sodium chloride (NaCI) followed by 0.1 M sodium 
acetate buffer (pH 4 with acetic acid) containing 0.5 M NaCI, and a final wash of 
distilled water. After each of these washes, the solution was centrifuged for 1 
minute at 10,000 RCF and the upper aqueous layer was removed. This process 
of washing the beads, centrifuging, and removing the upper aqueous layer was 
repeated with 0.1 M sodium bicarbonate and three times with 1X PBS. Both sets 
of beads were stored in 3 M NaCI at 4°C overnight. 
The following day, the beads were centrifuged at 10,000 RCF and the 
upper aqueous layer was removed. The beads were washed three times with 10 
volumes each of 1X PBS, centrifuged at 10,000 RCF, and followed by removal of 
the upper aqueous layer. PBS (1X) was added to each tube to create a 1:1 slurry 
of peptide beads:1X PBS. In a 1.5 ml_ microcentrifuge tube, 100 uL of the 
peptide bead slurry were added to 200 uL of each antibody serum, including the 
7 
pre-immunization serum, and shaken on the rocker for one hour at room 
temperature. The bead-antibody solutions were washed five times with 1 mL 1X 
NP40 buffer (140 mM NaCI, 20 mM tris(hydroxymethyl)aminomethane-
hydrochloric acid (Tris-HCI), 1mM ethylenediaminetetraacetic acid (EDTA), 1% 
Tergitol-type NP-40) with the top aqueous layer removed after each wash. 
Fifty uL 5X sample buffer (250 mM Tris-HCI pH6.8, 10% SDS, 30% 
Glycerol, 0.02% bromophenol blue) were combined with 2.5 uL B-
mercaptoethanol and added to each bead-antibody solution and boiled for three 
minutes. Forty uL of each sample buffer/bead-antibody solution was added to the 
well of a 4-15% Tris-HCI gel. Ten uL Precision Plus Dual Color Standards (Bio-
Rad Laboratories) were added to each of two wells on each gel. The gel was run 
in a 1X running buffer of Tris/SDS/glycine (Bio-Rad Laboratories) at 20 mA/gel 
for 90 minutes using a Power Pac Basic with Mini Trans Blot (Bio-Rad 
Laboratories). 
A polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories) was 
wetted in 100% methanol for 1 minute, and then both the gel and the membrane 
were equilibrated for 5 minutes in transfer buffer (22 mL 2M Tris, 168 mL 2M 
Glycine, 350 mL 20% MeOH, 1210 mL de-ionized water). The gel was 
transferred onto the PVDF membrane in transfer buffer for two hours at 75V on 
ice. The membranes were incubated with anti-rabbit IgG (FC) AD Conjugate 
antibodies (Promega, Madison, Wl) at 1:5000 (1 part antibody to 5000 parts 1% 
BLOTTO) (blotting-grade blocker, Bio-Rad Laboratories) in 1X Tween/Tris-
buffered salt solution (TTBS) (10X TTBS: 2 mL Tween 20, 12.1 g Tris, 17.4 g 
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NaCI, 200 ml_ de-ionized water) for 30 minutes at room temperature with 
agitation on a Red Rocker Model PR50 (Hoefer Scientific Instruments, San 
Francisco, CA). The membranes were washed two times in 5 ml_ 1X TTBS for 15 
minutes each. Western blue (Promega Corp, Madison, Wl) was added to each 
membrane and agitated until the color developed. The membranes were rinsed 
with water and air dried. 
Antibody Purification 
Two sera from each rabbit, containing the highest relative concentration of 
antibody and highest specificity for truncated mortalin, were chosen for 
purification. Antibodies from each serum were purified utilizing an identical 
apparatus (Figure 2). Prior to purification, small tubing and stop-cocks were 
washed sequentially with water, 95% ethanol, and water. A large ring stand was 
equipped with two clamps capable of holding a 3 ml_ syringe. Stop-cocks were 
added to the bottom of two 3 ml_ syringes where the needle is typically attached. 
A small amount of non-siliconized, glass wool in a loose ball was pushed to the 
bottom of the syringe with a transfer pipette (Figure 2). 
Syringes in this apparatus were filled with 1X PBS to remove any air 
bubbles, and 1X PBS was allowed to pass through until just above the glass 
wool. The BSA-beads were added to the top syringe, and the peptide-beads 
were added to the bottom syringe (Figure 2). Sera from each of the four bleeds 
were purified separately, using two columns for each. 200 ml_ 1X PBS were run 
through the eight columns to wash the beads. The columns were stored at 4°C 
until use. 
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The apparatus was assembled with the columns as described above 
(Figure 2), and 200 ml_ 1X PBS were passed through the columns to check for 
leaks and to ensure that the beads were hydrated. Fifteen ml_ of the antibody 
serum were passed through first the top and then the bottom columns, and the 
column void (liquid passing through the bottom column) was collected. The 
columns were washed with 10 ml_ 1X PBS. The tubing between the top and 
bottom columns was removed from top column. Fifty ml_ 1X PBS were passed 
through the bottom column to wash away loosely-associated antibodies. The 
peptide column was washed with 20 ml_ 0.5 M NaCI (20 column washes). 
Dialysis tubing was boiled, and the remaining NaCI in the column was removed 
with a transfer pipette. 
Three ml_ 3.5 M magnesium chloride (MgCfe) were added to the column. 
The first 5 ml_ 3.5 M MgCI2 voided from each column were collected in clean 15 
mL Falcon tubes and labeled Elute 1. A knot was tied in the dialysis bag and the 
Elute 1 flow through was added to the dialysis bag, which was closed with a 
floating clip. An air bubble was kept in the tubing to ensure the bag would float, 
and the bag was placed in 1 L 1X PBS. Another 5 mL 3.5 M MgCb were 
collected, labeled Elute 2, and the dialysis process repeated. MgCI2 (4.5 M) was 
passed through the column and the first 5 mL and second 5 ml voided and 
labeled as Elutes 3 and 4. These were also placed in separate dialysis bags. 
The four elutes were placed in 1 L 1X PBS at 4°C overnight with magnetic 
stirring. The next day, the 1X PBS was changed for fresh PBS, and the elutes 
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were left at 4°C overnight with continued stirring. The four elutes were placed into 
separate 15 mL Falcon tubes. 
An Ultrospec 2000 (Pharmacia Biotech, Uppsala, Sweden) was used to 
determine the concentration of each of the purified antibodies'. At 280 nm, a 
reading of 0.1 equaled approximately 0.1 mg/mL of antibody. The purified 
antibody solutions were labeled and frozen at -20°C. 
Protein Extraction 
An NE-PER protein extraction kit (Pierce, Rockford, Illinois) was used to 
isolate the cytoplasmic and nuclear protein fractions from CCH. In a 
microcentrifuge tube, 1.5 mL of CCH were centrifuged at 2,000 RCF for 10 
minutes. This was repeated a second time to increase the amount of CCH 
collected, removing the supernatant prior to addition of CCH and after the second 
centrifugation. 200 uL ice-cold CER I (from the NE-PER kit) were added to the 
CCH and the mixture was vortexed to resuspend the pellet. The tube was 
incubated on ice for 10 minutes. Eleven uL CER II (from the NE-PER kit) were 
added to the tube, vortexed, and incubated for an additional sixty seconds. The 
tube was centrifuged at 18,000 RCF for 5 minutes. The supernatant was placed 
in a clean 1.5 mL tube and labeled as the cytoplasmic protein fraction. 
The pellet was resuspended in 100 uL ice-cold NER by vortexing, and 
incubated on ice for 40 minutes while vortexing the tube every 10 minutes. The 
sample was centrifuged at 18,000 RCF for 10 minutes, and the supernatant was 




Two hundred uL 5X sample buffer were combined with 10 uL p-
mercaptoethanol in a 1.5 ml_ tube. Thirty-two uL cytoplasmic CCH protein and 8 
uL sample buffer were combined for each antibody sample tested. This protein 
solution was denatured in boiling water for three minutes. Ten uL precision plus 
dual color protein ladder (Bio-Rad Laboratories) were added to every other well 
in a 4-15% Tris-HCI gel. 40 uL of the protein/buffer solution were added to the 
remaining five wells. The gel was run for two hours at 20 mA/gel in 1X running 
buffer. The resulting gels were transferred to a PVDF membrane overnight at 90 
mA at 4°C. 
The resulting PVDF membrane was cut to yield one protein sample and 
one ladder for each section. Each membrane was placed in 1% Blotto in 1X 
TTBS with a 1:100 dilution of one of the four first elutes of each purified antibody. 
The fifth membrane was placed in 1% Blotto in 1X TTBS with a 1:1000 dilution of 
MAMOT (Mya arenaria mortalin protein) fraction 2 antibodies, antibodies 
previously purified, for a positive control. MAMOT fraction 2 is more concentrated 
than the purified truncated mortalin antibodies, allowing for a larger dilution factor 
in 1% Blotto. The MAMOT fraction 2 antibody recognizes a region downstream of 
the splice site of mortalin, making it possible to identify both truncated and full-
length mortalin. Membranes were agitated for 3 hours at 4°C. Each membrane 
was washed two times with 5 ml_ 1X TTBS for 15 minutes each. Western blue 
was added to each membrane and agitated until the color developed at which 
point the membranes were rinsed with sterile water and air dried. 
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Figure 2. Diagrammatic representation of the peptide column used for purification 
of each serum. After the serum was run through the two columns, the tubing was 
removed from the bottom of the top syringe filled with BSA-beads. 
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III. RESULTS 
Establishing Relative Antibody Concentrations 
Sera from the seven bleeds from each rabbit (2273 and 2274) and the 
pre-immune bleed were evaluated for the highest antibody titer. The bands on 
the PVDF membranes were the heavy chain of the antibodies within each serum 
from rabbit 2273 (Figure 3) and rabbit 2274 (Figure 4) that was tested. As a 
result of heat and detergent treatment, the heavy and light chains had separated. 
Once separated, the light chain ran off the gel, leaving the heavy chain to be 
visualized by the secondary anti-rabbit antibodies. 
Figures 3 and 4 indicate the results of the seven different bleeds from 
rabbits 2273 and 2274. Lanes with the most intense staining contained higher 
relative antibody concentrations. The pre-immune sera contained no antibodies 
that recognized truncated mortalin (Figures 3 and 4). It is possible that the slight 
shading observed within the pre-immune sera was unspecific binding of 
antibodies to mortalin prior to purification. The bleed from 10/1/07 for rabbit 2273 
had the highest relative concentration of antibody against truncated clam mortalin 
(Figure 3). The bleed from 10/15/07 for rabbit 2274 had the highest relative 
concentration of antibody against truncated clam mortalin (Figure 4). All the other 
bleeds, except the pre-immune serum, had similar concentrations of antibodies 
against truncated clam mortalin (Figures 3 and 4). 
Antibody Purification 
Quantification of antibody concentration for the four purified antibody 
washes is shown in Table 1. With the exception of 2273 10/1/07, the first elute 
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had the highest antibody concentration (Table 1). The fourth elute had the lowest 
antibody concentration (Table 1). 
Antibody Verification 
Immunoblots of the CCH cytoplasmic protein showed proteins at 
approximately 28 and 45 kD in lanes 1 and 3 (Figure 5). Lanes 2 and 4 contained 
a single protein at approximately 68 kD (Figure 5). Lane 5 contained two proteins 
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Figure 3. Immunoblot of each serum from rabbit 2273. Lane 1: 11/22/07; Lane 2: 
11/15/07; Lane 3: ladder; Lane 4: 11/12/07; Lane 5: 10/29/07; Lane 6: 10/15/07; 
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Figure 4. Immunoblot of each serum from rabbit 2274. Lane 1: 11/22/07; Lane 2: 
11/15/07; Lane 3: ladder; Lane 4: 11/12/07; Lane 5: 10/29/07; Lane 6: 10/15/07; 


































Table 1. The concentration in mg/ml of antibodies in each purified sera. 
Absorbance 280 nm. 
18 























Figure 5. Immunoblot of the CCH cytoplasmic proteins; each segment contains 
first the ladder and second the protein extract. Segment 1: 2273 serum 10/1/07; 
Segment 2: 2274 serum 10/15/07; Segment 3: 2273 serum 11/22/07; Segment 4: 
2274 serum 11/22/07; Segment 5: MAMOT fraction 2. 
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IV. DISCUSSION 
Immunoblotting indicated which of the six bleeds should be purified for 
each rabbit. The immunoblot for rabbit 2273 showed that the 10/1/07 serum had 
the highest concentration of antibodies out of the six 2273 sera. The 10/15/07 
serum had the highest concentration of antibodies out of the six 2274 sera. The 
other sera for each rabbit had similar, but lesser concentrations. The pre-immune 
serum had no antibodies for truncated clam mortalin. 
Based on higher concentrations of antibodies and antibody specificity, 
only two sera from each rabbit were purified. The first to be chosen were sera 
10/1/07 from 2273 and 10/15/07 from 2274 based on the higher antibody 
concentrations. The sera from 11/22/07 of both 2273 and 2274 were also 
purified. Although the later sera contained lower concentrations of antibodies, 
they should contain antibodies with higher specificity for the peptide resulting 
from more precise configurations for the peptide conjugate administered. Time 
allows for more precise B cell differentiation towards the antigen, in this case our 
peptide, generating high specificity antibodies. 
The second immunoblot of the newly purified antibodies showed that 
rabbit 2273 had produced antibodies with some specificity for the truncated 
mortalin splice site, but not specific enough to recognize truncated mortalin. Two 
proteins were recognized by the purified antibodies from rabbit 2273, neither of 
which were truncated mortalin. Both purified antibodies from 2274 (10/15/07 and 
11/22/07) recognized truncated mortalin only (located at 68 kDa). MAMOT 
fraction 2 (an antibody generated for the region downstream of the splice site of 
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mortalin), recognized both truncated mortalin, at 68 kDa, and full-length mortalin, 
at 74 kDa. These results show that rabbit 2274 11/22/07 first elute antibody is 
specific for the truncated clam mortalin and has the highest relative concentration 
(Table 1, Figure 5). 
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Chapter 2 - LOCALIZATION OF TRUNCATED MORTALIN PROTEIN IN 
CANCEROUS CLAM HEMOCYTES (CCH) 
Objective II: To use the antibody developed in Objective I to localize truncated 
mortalin protein within cancerous clam hemocytes. 
Hypothesis II - Truncated mortalin is located near the nuclear pores in cancerous 
clam hemocytes. 
Hypothesis III - Truncated mortalin antibodies can be transfected into cancerous 
clam hemocytes where they will block mortalin from tethering of p53, followed by 
apoptosis. 
II. Materials and Methods 
Generation of CCH Cytospins 
Clams were classified as normal (0% round, non-motile CCH; 100% 
attached, motile clam hemocytes), early incipient cancerous (1-50% round, non-
motile CCH), late incipient cancerous (50-99% CCH), or fully cancerous (100% 
CCH). CCH were only withdrawn from clams classified as fully cancerous. CCH 
were withdrawn from the pericardial sinus of clams with 100% cancerous 
hemocytes using a 21 gauge needle attached to a 3 mL syringe. Sea water was 
sterile filtered using a .22 urn mesh. A cell suspension of 2.2x106 CCH/mL of sea 
water was prepared. 100 uL diluted CCH were placed onto poly-lysine coated 
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slides and spun at 133 RCF for eight minutes by a Shandon Cytospin 3 (Thermo 
Scientific, Rockford, Illinois) for optimum coverage and spread. 
Fixation and Embedding of CCH 
Hemolymph, CCH, was removed from the pericardial sinus of clams and 
centrifuged at 14,000 RCF for 15 seconds with a Beckman Coulter Microfuge 
22R Centrifuge (Fullerton, CA). The supernatant was removed and 1 ml_ 2.5% 
glutaraldehyde in filtered sea water was added to the tube. The solution was 
vortexed until the pellet floated and placed on a Glas Col mini-rotator (Terre 
Haute, IN) at 35 rpm for 1 hour. The tube was centrifuged again. The supernatant 
was removed, and 1ml of distilled water was added. The solution was vortexed 
until the pellet floated and placed on a mini-rotator at 35 rpm for 10 minutes. The 
tube was centrifuged again and the supernatant removed. 
The pellet was dehydrated in increasing concentrations of ethanol (20%, 
50%, 70%, 95%, and 100%), rotated at 35 rpm for 10 minutes, centrifuged at 
14,000 RCF for 15 seconds, and the supernatant removed. The pellet in 100% 
ethanol was centrifuged at 10,000 RCF for 30 seconds. The supernatant was 
removed and 500 uL of a 1:1 solution of 100% ethanol to Pelco Acrylate Resin 
(Ted Pella Inc., Redding, CA) were added to the pellet. 
The pellet was left at room temperature for 1 hour and agitated every 15 
minutes with a transfer pipette. The solution was centrifuged at 10,000 RCF for 
30 seconds and the supernatant was removed. 250 uL Pelco Acrylate Resin 
were added to the pellet and incubated for 1 hour, agitating every 15 minutes 
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with a transfer pipette. The solution was centrifuged and the supernatant 
removed. This process was performed twice to remove any ethanol residue. 
Finally, 250 uL Pelco Acrylate Resin were added to the pellet. The pellet 
and acrylate resin were placed into a gelatin capsule (EMS, Hatfield, PA), 
centrifuged at 10,000 RCF for 30 seconds, and allowed to polymerize for 
approximately 12 hours at 60°C. The gelatin capsule was filled to the top with the 
acrylate resin and incubated at 60°C for 12 hours. Five um sections were cut 
using a Reichert OMU3 ultramicrotome with glass knives and heated in a drop of 
water on poly-lysine coated slides until dry. 
Localization of Truncated Mortalin within CCH Embedded in Plastic and as 
Cytospins 
Sections of CCH on poly-lysine coated slides were placed in a Coplin jar 
containing de-ionized water for 10 minutes to start the hydration process of the 
CCH sections. Cytospins of CCH prepared as described above were fixed and 
permeabilized in cold acetone for 10 minutes. Both sets of slides were placed in 
a Coplin jar with 0.3% H2O2 in methanol to initiate permeabilization of the CCH 
sections and rocked for 30 minutes on a Red Rocker Model PR50 (Hoefer 
Scientific Instruments, San Francisco, CA). The slides were rocked in Vectastain 
buffer (1.2 g mono-basic NaP04, 9 g NaCI, 1 ml Trition X-100, and final volume 1 
liter with de-ionized water) for 10 minutes. 
A Vectastain ABC kit for rabbit IgG and a DAB substrate kit, 3,3'-
diaminobenzidine (Vector laboratories Inc, Burlingame, CA) provided the normal 
serum, secondary-antibody, ABC solutions, DAB, and DAB enhancer. In the end, 
the two kits combined attach a substrate to the IgG antibody and allow 
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visualization via a colorimetric reaction. The slides were incubated with dilute 
normal serum (3 ml_ Vectastain buffer and 1 drop of concentrated normal serum 
from kit) in a hydration chamber for 20 minutes. The hydration chamber 
consisted of a Petri dish with a wet thin sponge on the bottom, two thin, round 
plastic tubes at either end of the dish (upon which slides rested), and a second 
Petri dish as a lid. Both Petri dishes were covered with tin-foil on the outside to 
protect the slides from light during incubation. 
The slides were incubated overnight (24 hours) in the hydration chamber 
with 50 uL of a 1:4 solution of the clam polyclonal antibody MAMOT fraction 2 
(specific for both truncated and full-length mortalin) or 2274 11/22/07 elute 1 
(specific for truncated mortalin): dilute normal serum. A negative control slide 
with sections of CCH was incubated with 50 ul dilute normal serum. The following 
day, another 50 ul of 1:4 solution of antibody:dilute normal serum or just dilute 
normal serum (negative control) was added to the CCH slides in the hydration 
chamber and incubated for a second night in the chamber for maximum delivery 
into the CCH. The CCH cytospin slides were continued to the 10 minute 
Vectastain buffer step below. 
The CCH slides were incubated in Vectastain buffer for 30 minutes, while 
the CCH cytospin slides were incubated in Vectastain buffer for 10 minutes. The 
embedded CCH slides were incubated overnight while the CCH cytospin slides 
were incubated for 1 hour in the hydration chamber in secondary goat anti-rabbit 
antibody solution (2.5 ml of vectastain buffer, 1 drop of dilute normal serum from 
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kit, and 1 drop of concentrated secondary antibody from kit, a biotin-labeled goat 
antibody to rabbit IgG heavy chain). 
The following day for embedded CCH slides (or an hour after having 
incubated in the secondary antibody solution for CCH cytopsins), the slides were 
rocked in Vectastain buffer for 10 minutes. The ABC solution contained avidin, 
which binds multiple sites on biotin at the site of the primary antibody/protein of 
interest and was made 30 minutes prior to use (2.5 ml_ of vectastain buffer, 1 
drop of A from kit, Avidin DH solution, and 1 drop of B from kit, biotinylated 
enzyme). The slides were incubated with the ABC solution for 30 minutes in the 
hydration chamber. The slides were rocked in Vectastain buffer for 10 minutes to 
remove excess ABC solution while maintaining permeability of the CCH sections. 
The DAB Substrate Kit 3,3'-diaminobenzidine was used to react with the 
avidin substrate previously attached to the slides from the ABC solution. The 
slides were incubated in the hydration chamber with 400 uL DAB (2.5 ml_ water, 
1 drop buffer from kit, 2 drops DAB from kit, and 1 drop H202 from kit) until a tan 
color developed, about 60-90 minutes depending on color development. The 
slides were rinsed in water and placed in 0.05 M sodium bicarbonate, pH 9.6, for 
10 minutes. The slides were incubated with DAB Enhancing Solution (Vector 
Laboratories Inc, Burlingame, CA) for 20 seconds. The DAB Enhancing Solution 
enhances the reaction product from DAB to increase the sensitivity of the kit. 
The CCH slides were rinsed in de-ionized water and air dried. The CCH 
cytospin slides were dehydrated for 1 minute each in an increasing ethanol 
series followed by xylene (50%, 70%, 95%, and 100% ethanol). The slides were 
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removed from xylene and immediately mounted under a 2x2 cm coverslip using 
Permount (Fisher Scientific). The slides were examined at 63X bright field (BF) 
on a Zeiss Axioplan II MOT equipped with epifluorescence, an AxioCam MR 
camera, and AxioVision 4.3 software (Carl Zeiss, Inc., Thornwood, NJ). 
Transfection of Antibodies into CCH using Chariot 
MAMOT fraction 2 (positive control), rabbit 2274 11/22/07 elute 1, and 
cytochrome C antibodies were each transfected into a set of CCH. For each set, 
and for a negative control, 2 uL of Chariot Protein Delivery Reagent (Active Motif, 
Carlsbad, CA) were combined with 50 uL of nuclease-free water. Chariot delivers 
antibodies into live cells by one of two possible ways: 1) by creating a pore in the 
cell membrane which allows the antibody to flow into the cell or 2) by attaching to 
the antibody on the outside of the cell and flipping it to the inside of the cell. Of 
the two methods, the one responsible for transfection has not been verified. 
Because there were four different treatments (3 antibodies, MAMOT, rabbit 2274, 
and cytochrome C, and a negative control), 8 uL of Chariot were added to 200 uL 
of nuclease-free water (Chariot Protein Delivery Reagent kit). 
1.5 ug antibody (MAMOT fraction 3, rabbit 2274 11/22/07 elute 1, or 
cytochrome C rabbit polyclonal IgG antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) were brought to a final volume of 50 ul_ with 1X PBS. The 50 uL 
antibody solution was combined with 52 uL of the Chariot-water solution. For the 
negative control, 52 uL of the Chariot-water solution were combined with 50 uL 
1X PBS. The antibody-Chariot solution was incubated at room temperature for 30 
minutes. 
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1.5 mL of CCH were removed from the pericardial sinus of a 100% 
cancerous clam as described above and placed in a microcentrifuge tube on ice. 
The concentration of CCH was determined using a hemocytometer. CCH 
(0.1x106 cells) were added to each of the three chariot-antibody solutions as well 
as to the negative control. The volume was brought to 150 uL with filtered sea 
water. The four solutions containing CCH were incubated at 4°C for 90 minutes. 
A first set of cytospins was created for each cell solution with 72 uL of the cell 
solution per slide. The cytospins were spun at 133 RCF for 8 minutes. The 
remainder of each CCH solution was left to incubate for an additional 90 minutes 
at 4°C. A second set of cytospins was spun at 133 RCF for 8 minutes with 72 uL 
of the cell solution. 
Localization of Truncated Mortalin within Chariot-Treated CCH 
Chariot-treated CCH cytospins were incubated in cold acetone for 10 
minutes. The slides were rinsed with Vectastain buffer and placed in 0.3% H2O2 
in methanol for 30 minutes. The slides were incubated in Vectastain buffer for 10 
minutes followed by incubation in the hydration chamber with dilute normal 
serum for 20 minutes. 
To detect truncated mortalin antibody, chariot-treated CCH were 
incubated in the hydration chamber with secondary antibody solution for 1 hour. 
Preparation of these slides was as in the above section Localization of Truncated 
Mortalin within CCH as Cytospins. The slides were examined at 63X bright field 
(BF) on a Zeiss Axioplan II MOT equipped with epifluorescence, an AxioCam MR 
camera, and AxioVision 4.3 software. 
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III. RESULTS 
Localization of Truncated Mortalin within CCH Embedded in Plastic 
These preparations were used to determine whether perinuclear 
localization of clam mortalin was attributable to full length, to truncated mortalin, 
or to both7'12. Neither the truncated nor the full-length antibody detected any 
variant of mortalin within the CCH embedded in plastic (Figure 6). 
Localization of Truncated Mortalin in CCH cytospins 
Results depended on which primary antibody was initially transfected into 
CCH. Full length clam mortalin antibody (MAMOT), which recognizes both full 
length and truncated variants of clam mortalin, indicated that clam mortalin was 
evenly distributed in the cytoplasm (Figure 7-1). Truncated clam mortalin was 
restricted to small spots within the cytoplasm and not in the nuclei of CCH 
(Figure 7-2). Truncated clam mortalin was not detected in control CCH (Figure 7-
3). 
Localization of Truncated Mortalin within Chariot-Treated CCH 
When CCH were treated with MAMOT (Figure 8-1), truncated mortalin antibody 
(Figure 8-2), and cytochrome C (Figure 8-3) similar distributions of protein were 
observed in cytoplasm. None of these proteins was detected in control CCH 
(Figure 8-4). Following all three treatments, the structure of CCH differed from 
that of untreated CCH. The plasma membranes of CCH, independent of 
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Figure 6. CCH embedded within Pelco Acrylate Resin: 1) clam full-length 
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Figure 7. Cytospins of CCH with treated with: 1) MAMOT (fraction 2), 2) clam 
truncated mortalin antibody (2274 11/22/07 elute 1) and 3) control; N = nucleus; 
















Figure 8. CCH transfected with: 1) MAMOT (fraction 2), 2) clam truncated 
mortalin antibody (2274 11/22/07 elute 1), 3) cytochrome C antibody and 4) 
control; N = nucleus; Scale bars = 10 urn. 
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IV. DISCUSSION 
Localization of Truncated Mortalin within CCH Embedded in Plastic 
In CCH embedded in Pelco Acrylate Resin, there was no evidence that 
proteins had been localized using MAMOT (full-length and truncated mortalin) 
antibodies (Figure 6). Truncated and full-length mortalin proteins are both found 
in high concentration within CCH as demonstrated by results from western 
blotting7. CCH treated with full-length antibody (MAMOT fraction 2) should have 
identified both of these proteins as indicated in Walker et al., 2006 and did not do 
so in these preparations. This suggests that the antibodies we used did not 
penetrate the hydrophilic acrylate resin. 
Localization of Truncated Mortalin within CCH as Cytospins 
Control CCH that were not incubated with either primary antibody did not 
stain (Figure 7-3). Localization of clam full-length and truncated mortalin within 
CCH is illustrated in Figures 7-1 and 7-2 respectively. Their cytoplasmic 
localization within CCH is unique. Clam full-length mortalin is evenly distributed in 
the cytoplasm (Figure 7-1). Clam truncated mortalin is localized to small spots at 
discrete locations in the cytoplasm (Figure 7-2). While some of these spots 
surround the nucleus, it is likely that truncated mortalin is associated with 
mitochondria, which have similar cytoplasmic distribution near the nucleus and 
also throughout the cytoplasm. In humans, mortalin is transported to and 
ultimately located in the mitochondrial matrix. My results seem to refute 
Hypothesis II which proposed that truncated mortalin would be localized 
exclusively around the nuclear pores. 
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Localization of Truncated Mortalin within Chariot Treated CCH 
Control CCH that were not incubated with antibody did not stain (figure 8-
4). Figures 8-1 through 8-3 demonstrated a generalized darkening of all cellular 
components following transfection with all three antibodies (truncated and full-
length mortalin antibody and cytochrome C) in Chariot treated CCH. Such 
darkening is often observed under the conditions outlined in this study and is 
interpreted here as a failure to successfully transfect CCH in all cases. These 
results indicate that transfection with the Chariot system under the conditions 
outlined in the Materials and Methods above did not deliver truncated mortalin 
antibodies into CCH. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
Previous research indicates that mortalin is co-sequestered with p53 near 
the centriole or microtubular array in the cytoplasm of CCH, but not NCH7. The 
same study demonstrated that competitive inhibition of mortalin by the cationic 
inhibitor MKT-077 promoted access of wild-type p53 to the nucleus and in some 
cells induced apoptosis5'7. Genotoxic-stress to CCH, resulting from etoposide 
treatment, increases the levels of p53 mRNA as shown by QPCR and suggests 
that increased levels of p53 can lead to apoptosis5. 
Recently a splice variant of full-length clam mortalin, missing exon 3 was 
cloned12. My study was designed to develop an antibody that could differentiate 
truncated from full-length clam mortalin and to demonstrate the localization of 
truncated mortalin within the cytoplasm of CCH using the newly designed 
antibody. Based on the results in Walker et al., 2006, I hypothesized that 
truncated mortalin would be localized exclusively near or surrounding the nuclear 
pores in CCH. The results of this study demonstrate that truncated mortalin was 
localized at both the centrioles and the mitochondria as well as near the nucleus, 
although not uniformly localized near the nuclear pores as was hypothesized. 
Mortalin is a member of the Hsp-70 family of proteins that has been 
localized at multiple sites in transformed human cell lines. Although it is unclear 
how mortalin is delivered in different cell lines, multiple subcellular sites have 
been identified including, mitochondria, endoplasmic reticulum, cytoplasmic 
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vesicles, and cytosol15,16,17,18,19'20'21. The principle site for mortalin's function is 
mitochondria11'15'17'18'21. 
In an earlier study of CCH, mortalin was localized both perinuclearly and 
at mitochondria, respectively. The perinuclear localization of mortalin was 
documented in Walker et al (2006) where mortalin and p53 were co-localized 
near the nucleus in CCH, both in vivo and in vitro7. In the current study of CCH, it 
appears that truncated mortalin is localized both in the perinuclear regions of the 
CcH and at mitochondria, although this needs to be tested in conjunction with 
FITC labeled WGA and cytochrome C antibodies respectively. 
The transfection of antibodies into CCH using Chariot resulted in the 
darkening of all cellular components. All attempts at transfecting antibodies used 
in this study using Chariot methodology indicated that more studies need to be 
carried out to successfully transfect antibodies into CCH. 
Walker et al (2006) demonstrated the co-localization of p53 and mortalin 
within CCH but not NCH7. When this paper was published, the truncated variant 
of mortalin had not been detected. 
Although the current study indicates that truncated mortalin is confined to 
two main locations within CCH, perinuclear and mitochondrial, its role in p53 
sequestration has not been resolved. Since previous studies indicated p53 at 
perinuclear localization, it is possible that truncated mortalin will be found co-
localized with p53 in subsequent studies at perinuclear locations. If truncated 
mortalin is associated with mitochondria and with the nucleus, it is possible that it 
could be involved in both genotoxic and non-genotoxic stress related induction of 
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p53 when cytoplasmic sequestration of wild-type p53 is defeated in CCH. Both of 
these possibilities are dependent on the idea that truncated mortalin is able to 
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